Sarcolysine acridine

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 597796

CAS#: 53161-31-2

Description: Sarcolysine acridine is a bioactive chemical.


Chemical Structure

img
Sarcolysine acridine
CAS# 53161-31-2

Theoretical Analysis

MedKoo Cat#: 597796
Name: Sarcolysine acridine
CAS#: 53161-31-2
Chemical Formula: C26H26Cl3N3O2
Exact Mass:
Molecular Weight: 518.86
Elemental Analysis: C, 60.19; H, 5.05; Cl, 20.50; N, 8.10; O, 6.17

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Sarcolysine acridine;

IUPAC/Chemical Name: (S)-2-(acridin-9-ylamino)-3-(4-(bis(2-chloroethyl)amino)phenyl)propanoic acid hydrochloride

InChi Key: GGHBELMGCPMLSE-JIDHJSLPSA-N

InChi Code: InChI=1S/C26H25Cl2N3O2.ClH/c27-13-15-31(16-14-28)19-11-9-18(10-12-19)17-24(26(32)33)30-25-20-5-1-3-7-22(20)29-23-8-4-2-6-21(23)25;/h1-12,24H,13-17H2,(H,29,30)(H,32,33);1H/t24-;/m0./s1

SMILES Code: O=C(O)[C@H](CC1=CC=C(N(CCCl)CCCl)C=C1)NC2=C(C=CC=C3)C3=NC4=CC=CC=C42.[H]Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

Preparing Stock Solutions

The following data is based on the product molecular weight 518.86 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Joubert JP, Smit FJ, du Plessis L, Smith PJ, N'Da DD. Synthesis and in vitro biological evaluation of aminoacridines and artemisinin-acridine hybrids. Eur J Pharm Sci. 2014 Jun 2;56:16-27. doi: 10.1016/j.ejps.2014.01.014. Epub 2014 Feb 18. PubMed PMID: 24560941.

2: Iordanskiĭ AB, Prokof'eva-Bel'govska, Badaev NS, Kolosova MO, Zelenin AV. [Detection of specific fractions in heterochromatin by means of sarcolysine acridine]. Dokl Akad Nauk SSSR. 1971 Nov 1;201(1):213-6. Russian. PubMed PMID: 5002203.

3: Cao J, Lin G, Gong Y, Pan P, Ma Y, Huang P, Ying M, Hou T, He Q, Yang B. DNA-PKcs, a novel functional target of acriflavine, mediates acriflavine's p53-dependent synergistic anti-tumor efficiency with melphalan. Cancer Lett. 2016 Dec 1;383(1):115-124. doi: 10.1016/j.canlet.2016.09.029. Epub 2016 Sep 29. PubMed PMID: 27693638.

4: Kim M, Blum AB, Haslinger ML, Donahue MJ, Fisher DT, Skitzki JJ, Park IY. Quinacrine for extremity melanoma in a mouse model of isolated limb perfusion (ILP). Surg Today. 2015 Mar;45(3):355-62. doi: 10.1007/s00595-014-0952-y. Epub 2014 Jul 8. PubMed PMID: 24998594.

5: Saure C, Schroeder T, Zohren F, Groten A, Bruns I, Czibere A, Galonska L, Kondakci M, Weigelt C, Fenk R, Germing U, Haas R, Kobbe G. Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen. Biol Blood Marrow Transplant. 2012 Mar;18(3):466-72. doi: 10.1016/j.bbmt.2011.09.006. Epub 2011 Sep 29. PubMed PMID: 21963618.

6: Buzdar AU, Legha SS, Hortobagyi GN, Powell KC, Blumenschein GR, Bodey GP. AMSA and peptichemio in the treatment of advances metastatic breast cancer: a phase II study. Am J Clin Oncol. 1982 Aug;5(4):383-7. PubMed PMID: 6896794.

7: Koekemoer TC, van de Venter M, Kraus JL. JLK1486, a N,N-[(8-hydroxyquinoline)methyl]-substituted benzylamine analogue, inhibits melanoma proliferation and induces autophagy. Cell Prolif. 2014 Oct;47(5):416-26. doi: 10.1111/cpr.12127. Epub 2014 Aug 20. PubMed PMID: 25139616.

8: Karaivanov L. [Effect of physical and chemical factors on Pasteurella multocida bacteriophages]. Vet Med Nauki. 1976;13(4):65-72. Bulgarian. PubMed PMID: 8867.

9: Eksborg S, Ehrsson H. Drug level monitoring: cytostatics. J Chromatogr. 1985 May 10;340:31-72. Review. PubMed PMID: 2410436.

10: Hochman B. Analysis of chromosome 4 in Drosophila melanogaster. II. Ethyl methanesulfonate induced lethals. Genetics. 1971 Feb;67(2):235-52. PubMed PMID: 5569209; PubMed Central PMCID: PMC1212546.

11: Arrick BA, Nathan CF. Glutathione metabolism as a determinant of therapeutic efficacy: a review. Cancer Res. 1984 Oct;44(10):4224-32. Review. PubMed PMID: 6380705.

12: Kleinerman ES, Zwelling LA, Schwartz R, Muchmore AV. Effect of L-phenylalanine mustard, adriamycin, actinomycin D, and 4'-(9-acridinylamino)methanesulfon-m-anisidide on naturally occurring human spontaneous monocyte-mediated cytotoxicity. Cancer Res. 1982 May;42(5):1692-5. PubMed PMID: 6896012.

13: Dumont P, Atassi G, Tagnon HJ. Combination chemotherapy with AMSA on L1210 leukaemia and B16 melanoma. Eur J Cancer Clin Oncol. 1981 Sep;17(9):1017-21. PubMed PMID: 6895729.

14: Birshtein BK, Preud'homme JL, Scharff MD. Variants of mouse myeloma cells that produce short immunoglobulin heavy chains. Proc Natl Acad Sci U S A. 1974 Sep;71(9):3478-82. PubMed PMID: 4139712; PubMed Central PMCID: PMC433797.

15: Papadopoulou MV, Ji M, Bloomer WD. THNLA-1: a DNA-targeted bioreductive agent as chemosensitizer in vitro and in vivo. In Vivo. 1996 Jan-Feb;10(1):49-57. PubMed PMID: 8726811.

16: Papadopoulou MV, Ji M, Khan SH, Bloomer WD. Mechanisms involved in the potentiation of melphalan by the bioreductive compound THNLA-1 in vitro. Oncol Res. 1999;11(8):345-57. PubMed PMID: 10803738.

17: Bailey MJ, Smith IE. Correlation between experimentally and clinically demonstrated activity of two new cytotoxic agents in breast cancer. Anticancer Res. 1985 Jul-Aug;5(4):419-22. PubMed PMID: 3839994.

18: Meyn RE, Murray D, vanAnkeren SC, Bernard GS, Mellard DN, Hobbs ML. Isolation and characterization of nitrogen mustard-sensitive mutants of Chinese hamster ovary cells. Mutat Res. 1991 Mar;254(2):161-5. PubMed PMID: 1900571.

19: Bennett A, Melhuish PB, Patel S, Randles H, Stamford IF. Cancer in mice: effects of prednisolone or mepacrine alone and with cytotoxic drugs. Br J Cancer. 1987 Apr;55(4):385-8. PubMed PMID: 3580263; PubMed Central PMCID: PMC2001699.

20: O'Connor PM, Kohn KW. Comparative pharmacokinetics of DNA lesion formation and removal following treatment of L1210 cells with nitrogen mustards. Cancer Commun. 1990;2(12):387-94. PubMed PMID: 2265064.